KeyBanc raised the firm’s price target on Encompass Health (EHC) to $120 from $117 and keeps an Overweight rating on the shares. The firm notes Q4 results were impressive, punctuating a strong 2024 and reinforcing its positive long-term thesis. KeyBanc continues to view Encompass Health as an attractive growth stock that is insulated from ongoing policy-related uncertainty.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health: Strong Q4 2024 Performance and Positive 2025 Outlook
- Encompass Health’s Earnings Call Highlights Robust Growth
- Encompass Health’s Strong Performance and Strategic Expansion Drive Buy Rating by Ann Hynes
- Encompass Health: Strong Financial Performance and Growth Prospects Justify Buy Rating
- Encompass Health price target raised to $118 from $116 at Barclays